BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, July 2, 2024
See today's BioWorld
Home
» Enablement of genus claims gets its day in US high court
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Enablement of genus claims gets its day in US high court
March 27, 2023
By
Mari Serebrov
No Comments
A lot of eyes and ears were tuned to the U.S. Supreme Court’s March 27 argument in
Amgen Inc. v. Sanofi SA
with its focus on how much enablement is necessary in broad genus patent claims.
BioWorld
Regulatory
U.S.